Eli Lilly (LLY) Other Operating Expenses (2012 - 2019)

Eli Lilly has reported Other Operating Expenses for 8 years, with the latest figure at -$151.7 million in Q4 2019.

• For the quarter ending Q4 2019, Other Operating Expenses rose 21.24% year-over-year to -$151.7 million; the trailing twelve-month figure through Sep 2020 stood at -$151.7 million (up 75.39% YoY), and the FY2019 full-year result was -$9.1 billion, down 10.93% from the prior year.
• Other Operating Expenses for Q4 2019 stood at -$151.7 million, up from -$423.9 million in the prior quarter.
• The five-year high for Other Operating Expenses was $5.0 billion in Q4 2016, with the low at -$423.9 million in Q1 2019.
• Historically, Other Operating Expenses has averaged $220.6 million across 5 years, with a median of -$57.4 million in 2016.
• Annual changes were most pronounced in 2016 — Other Operating Expenses jumped 3526.71% — and 2017, when it slumped 793.41%.
• Eli Lilly's Other Operating Expenses stood at -$144.9 million in 2015, then jumped by 3526.71% to $5.0 billion in 2016, then slumped by 100.89% to -$44.4 million in 2017, then plunged by 333.78% to -$192.6 million in 2018, then climbed by 21.24% to -$151.7 million in 2019.
• The last three Other Operating Expenses figures came in at -$151.7 million (Q4 2019), -$423.9 million (Q1 2019), and -$192.6 million (Q4 2018), per Business Quant data.